“…A variety of ingredients such as the stable prostacyclin (PGI2) analogue OP-4183 (Goto et al, 1993), the p38 mitogen-activated protein kinase (MAPK) inhibitor FR167653 (Yoshinari et al, 2001), the NO donor sodium nitroprusside (Rodriguez et al, 1999), the platelet-activating factor (PAF) antagonist E5880 (Takada et al, 1995), calmodulin inhibitors (Anaise et al, 1990), Ca 2+ channel blockers such as nisoldipine (Takei et al, 1990;Vajdova et al, 2002), trophic factors (Ambiru et al, 2004), caspase or calpain inhibitors, S-adenosylmethionine (SAM) (Vajdova et al, 2002), insulin (Li et al, 2003), or fructose-1,6-biphosphate (FBP) (Moresco et al, 2004) were introduced into UW preservation solution, with promising results. However, none of these modifications to UW solution composition have found their way into routine clinical practice.…”